Labreportnew

Patient NAME : Mrs.
HIMANSHI Lab No : THS153180

Age/Gender : 29 Y 0 M 0 D /F Reg.Date : 25/May/2024 02:13PM
Barcode No : 823109 Collected : 25/May/2024 02:21PM
Referred By : Dr.SELF Reported : 25/May/2024 04:02PM
Client Name :DIGAMBAR PATH LAB Report Status : Final Report
DEPARTMENT OF HAEMATOLOGY
THS HEALTH CHECK PROFILE-IV
Test Name Result Unit Bio. Ref. Range Method
COMPLETE BLOOD COUNT

Sample Type : WHOLE BLOOD EDTA
HAEMOGLOBIN (HB) 12.8 gm/dl 12.0-15.0 Cyanide-free method
PCV/HAEMATOCRIT 42.4 % 40-50 Numeric Integration
RBC COUNT 4.96 10^6/uL 4.5-5.5 Electrical impedance
MCV 85.6 fL 83.0-101.0 Automated/Calculated
MCH 25.7 pg 27.0-32.0 Automated/Calculated
MCHC 30.1 g/dl 31.5-34.5 Automated/Calculated
RDW-CV 14 % 11.6-14.0 Automated/Calculated

RDW-SD 44.1 fL 39-46 Calculated
PLATELET COUNT 512 10^3/uL 150-410 Electrical impedance
TOTAL LEUCOCYTE COUNT (TLC) 10.00 10^3/uL 4.0-10.0 Electrical impedance
DLC (Differential Leukocyte Count.)

NEUTROPHIL 69 % 40-80
LYMPHOCYTE 24.1 % 20-40
EOSINOPHIL 2.0 % 01-06
MONOCYTE 4.2 % 02-10
BASOPHIL 0.7 % 00-01
ABSOLUTE NEUTROPHIL COUNT 6.90 10^3/uL 2-7 Automated Calculated
ABSOLUTE MONOCYTE COUNT 0.42 10^3/uL 0.20-1.0 Automated Calculated
ABSOLUTE LYMPHOCYTE COUNT 2.41 10^3/uL 1-3 Automated Calculated
ABSOLUTE EOSINOPHIL COUNT 0.20 10^3/uL 0.02-0.50 Automated Calculated
ABSOLUTE BASOPHIL COUNT 0.07 10^3/uL 0.02- 0.10 Automated Calculated
MPV 11.6 fL 8.60-15.50 Calculated
PDW 15.9 fL 8.30-25.00 Calculated
NEUTROPHIL-LYMPHOCYTE RATIO 2.86
LYMPHOCYTE-MONOCYTE RATIO 6
PCT 0.6 % 0.15-0.62
Page 1 of 12
Patient NAME : Mrs.HIMANSHI Lab No : THS153180
ERYTHROCYTE SEDIMENTATION RATE

ERYTHROCYTE SEDIMENTATION RATE 18 mm/ hr 1-10 Westergren
COMMENTS:
ESR is an acute phase reactant that indicates the presence and intensity of an inflammatory process. It is never diagnostic of a specific
disease. It is used to monitor the course or response to treatment of certain diseases. Extremely high levels are found in cases of
malignancy, hematologic diseases, collagen disorders, and renal diseases. · Increased levels may indicate: Chronic renal failure (e.g.,
nephritis, nephrosis), malignant diseases (e.g., multiple myeloma, Hodgkin disease, advanced Carcinomas), bacterial infections (e.g.,
abdominal infections, acute pelvic inflammatory disease, syphilis, pneumonia), inflammatory diseases (e.g. temporal arteritis, polymyalgia
rheumatic, rheumatoid arthritis, rheumatic fever, systemic lupus erythematosus [SLE]), necrotic diseases (e.g., acute myocardial infarction,
necrotic tumor, gangrene of an extremity), diseases associated with increased proteins (e.g., hyperfibrinogenemia, macroglobulinemia),
and severe anemias (e.g., iron deficiency or B12 deficiency).
Falsely decreased levels may indicate Sickle cell anemia, spherocytosis, hypofibrinogenemia, or polycythemia vera.
Page 2 of 12
Glycosylated hemoglobin (HbA1c)

HbA1c 5.2 % 4.0-6.40 HPLC
ESTIMATED AVG. GLUCOSE 102.54 mg/dl Calculated
ESTIMATED BLOOD AVG. GLUCOSE 5.68 mmol/L 3.46 - 7.92 Calculated
INTERPRETATION:
Result A1C
Normal <5.7 %
Prediabetic 5.7-6.4 %
Diabetic >=6.5%
Remarks:
1. HbA1c is used for monitoring diabetic control. It reflects the estimated average glucose (eAG).
2. HbA1c has been endorsed by clinical groups & ADA (American Diabetes Association) guidelines 2017, for diagnosis of diabetes using a
cut-off point of 6.5%.
3. Trends in HbA1c are a better indicator of diabetic control than a solitary test.
4. Low glycated haemoglobin(below 4%) in a non-diabetic individual are often associated with systemic inflammatory diseases, chronic
anaemia(especially severe iron deficiency & haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
5. To estimate the eAG from the HbA1C value, the following equation is used: eAG(mg/dl) = 28.7*A1c-46.7
6. Interference of Haemoglobinopathies in HbA1c estimation.
A. For HbF > 25%, an alternate platform (Fructosamine) is recommended for testing of HbA1c.
B. Homozygous hemoglobinopathy is detected, fructosamine is recommended for monitoring diabetic status
C. Heterozygous state detected (D10/ turbo is corrected for HbS and HbC trait).
7. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control.
Excellent Control - 6 to 7 %, Fair to Good Control - 7 to 8 %, Unsatisfactory Control - 8 to 10 % and Poor Control - > 10%.
Note : Hemoglobin electrophoresis (HPLC method) is recommended for detecting hemoglobinopathy.

Kindly correlate clinically.
*** End Of Report ***
Page 3 of 12
DEPARTMENT OF BIOCHEMISTRY
Plasma Fasting(F)
Sample Type : FLOURIDE PLASMA
Glucose-Fasting 92.7 mg/dl 70-100 GOD-POD
Comments:
Note: Fasting is defined as no caloric intake for at least 8 hours.
Conditions which can lead to lower postprandial glucose levels as compared to fasting glucose are excessive insulin release, rapid gastric
emptying & brisk glucose absorption.
Note: Additional tests available for Diabetic control are Glycated Hemoglobin (HbA1c), & Microalbumin urine.
Page 4 of 12
LIVER FUNCTION TEST

Sample Type : SERUM
TOTAL BILIRUBIN 0.73 mg/dl 0.01-1.4 Diazoniun Salt
BILIRUBIN DIRECT 0.41 mg/dL < 0.6 DIAZO
BILIRUBIN INDIRECT 0.32 mg/dL 0.1-1.1 Calculated
ASPARTATE AMINOTRANSFERASE (SGOT) 22.50 U/L 0-35.0 IFCC, Without Pyridoxal
Phosphate
ALANINE AMINOTRANSFERASE (SGPT) 19.70 U/L 0-45.0 IFCC, Without Pyridoxal
Phosphate
TOTAL PROTEIN 7.32 g/dl 6.40-8.30 Biuret
ALBUMIN 4.80 g/dl 3.5 - 5.2 Bromocresol-Green
GLOBULIN 2.52 gm/dl 2.50-3.50 Calculated
A/G RATIO 1.9 Ratio 1-2.5 Calculated
ALKALINE PHOSPHATASE 64 U/L 53 - 128 AMP
GAMMA GLUTAMYAL TRANSFERASE 28.40 U/L 0 - 38 Colorimetric Kinetic
SGOT/SGPT RATIO 1.14 Ratio <2.0 Calculated
INTERPRETATION
Bilirubin Elevated levels results from increased bilirubin production (eg hemolysis and ineffective erythropoiesis); decreased bilirubin
excretion (eg; obstruction and hepatitis); and abnormal bilirubin metabolism (eg; hereditary and neonatal jaundice).
Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in viral hepatitis; drug reactions, alcoholic liver disease
conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile
ducts like in Gallstones getting into the bile ducts tumors & Scarring of the bile ducts.
Increased unconjugated (indirect) bilirubin may be a result of hemolytic or pernicious anemia, transfusion reaction & a common metabolic
condition termed Gilbert syndrome.
AST levels increase in viral hepatitis, blockage of the bile duct ,cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia,
pancreatitis, hemochromatosis. Ast levels may also increase after a heart attck or strenuous activity.
ALT is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.
GGT may be higher with diabetes, heart failure, hyperthyroidism, or pancreatitis. Higher GGT levels also may mean liver damage from
heavy, chronic alcohol abuse. GGT levels that are higher than normal may also signal a viral infection
Elevated ALP levels are seen in Biliary Obstruction, Osteoblastic Bone Tumors, Osteomalacia, Hepatitis, Hyperparathyriodism, Leukemia,
Lymphoma, paget`s disease, Rickets, Sarcoidosis etc. Elevated serum GGT activity can be found in diseases of the liver, Biliary system and
pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-including drugs
etc.
Serum total protein, in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation
or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstrom's disease. Lower-than-normal levels may be due to:
Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition,
Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver
The SGOT/SGPT ratio is significantly elevated in patients with alcoholic hepatitis and cirrhosis (2.35±0.3) compared with patients with
postnecrotic cirrhosis (1.74±0.2), chronic hepatitis (1.3±0.17), obstructive jaundice (0.81±0.06) and viral hepatitis (0.74 ±0.07)
Page 5 of 12
LIPID PROFILE
Sample Type : SERUM
TOTAL CHOLESTEROL 195 mg/dl <200 CHOD-PAP
TRIGLYCERIDES 174.5 mg/dl <161 Glycerol phosphate
oxidase
H D L CHOLESTEROL 53.5 mg/dl 35.3-79.5 Direct homogeneous
LDL CHOLESTEROL 106.60 mg/dl <100 Measured, Liquid
Selective Detergent
VLDL 34.9 mg/dl 7-35 Calculated
T. CHOLESTEROL/ HDL RATIO 3.64 Ratio 0-11 Calculated
LDL / HDL RATIO 1.99 Ratio < 3.5 Calculated
NON- HDL Cholestrol 141.5 mg/dL Less than 130 Calculated
TRIGLYRIDES/HDL RATIO 3.26 Ratio 1.0-6.0 Calculated

TOTAL LIPIDS 423.00 mg/dL 210-490 Calculated
Interpretation
NCEP Recommendations Desirable Borderline Undesirable
Total Cholesterol (mg/dL) <200 200-239 >240
Triglyceride (mg/dL) <150 150-199 >200
LDL Cholesterol <130 130-159 >160
HDL Cholesterol >40 - <40
Lipid level assessments must be made following 10 to 12 hours of fasting, otherwise assay results might lead to erroneous interpretation.
NCEP recommends of 3 different samples drawn at intervals of 1 week for harmonizing biological variables that might be encountered in
single assays.
Note: LDL cholesterol cannot be calculated if triglyceride is >400 mg/dL (Friedewald's formula). Calculated values not provided/relieble for
LDL and VLDL
Page 6 of 12
KIDNEY Profile
Sample Type : SERUM
SERUM UREA 33.00 mg/dl 19.0-45.0 Urease
BLOOD UREA NITROGEN(BUN) 15.42 mg/dL 6.0-21.0 Calculated
Creatinine 0.73 mg/dL 0.7 - 1.3 Modified Jaffe
SERUM URIC ACID 4.8 mg/dl 3.5-7.2 Uricase
SODIUM 142.10 mmol/L 135-150 Direct ISE
POTASSIUM 3.7 mmol/L 3.50-5.0 Direct ISE
CHLORIDE 106 mmol/L 94-110 Direct ISE
BUN / cretanine ratio 21.1 Ratio 5.5-19.2 Calculated
Urea / Creatinine Ratio 45.21 Ratio 8-38 Calculated
Phosphorus 4.10 mg/dl 2.5-4.5 UV MOLYBDATE

CALCIUM, TOTAL 9.6 mg/dl 8.4-10.2 Arsenazo III
Estimated Glomerular Filtration Rate (eGFR) 100.18 mL/min/1.73m2 CKD-EPI equation
Reference range(eGFR):
Age(Years) Average eGFR((mL/min/1.73 m2 )
20 – 29 116
30 – 39 107
40 – 49 99
50 – 59 93
60 – 69 85
> 70 75
Chronic kidney disease:< 60 mL/min/1.73 m2
Kidney failure: <15 mL/min/1.73 m2
Interpretation:
The kidneys, located in the retroperitoneal space in the abdomen, are vital for patient health. They process several hundred liters of fluid a day and
remove around two liters of waste products from the bloodstream. The volume of fluid that passes though the kidneys each minute is closely linked to
cardiac
output. The kidneys maintain the body’s balance of water and concentration of minerals such as sodium, potassium, and phosphorus in blood and remove
waste by-products from the blood after digestion, muscle activity and exposure to chemicals or medications. They also produce renin which helps regulate
blood pressure, produce erythropoietin which stimulates red blood cell production, and produce an active form of vitamin D, needed for bone health.
Page 7 of 12
IRON PROFILE -I
Sample Type : SERUM
SERUM IRON 89.20 ug/dL 65-175 Ferrozine
TOTAL IRON BINDING CAPACITY 391.3 ug/dL 228-428 Calculations
UNSATURATED IRON BINDING CAPACITY 302.10 ug/dL 110 - 370 Ferrozine
TRANSFERRIN 270.04 mg/dL 215.00 - 365.00 Immunoturbidimetry
TRANSFERRIN SATURATION 22.8 % 20-50 %
INTERPRETATION:
SERUM IRON INCREASED IN:
-Hemosiderosis of excessive iron intake (e.g. repeated blood transfusion, iron therapy, iron containing vitamins).
-Decreased formation of RBCs (thalassemia, pyridoxal deficiency anaemia).
-Increased destruction of RBCs (hemolytic anaemia).
-Acute liver damage
-Acute iron toxicity
SERUM IRON DECREASED IN:

-Iron deficiency anaemia
-Normochromic anaemia of infections & chronic diseases
-Nephrosis
-Menorrhagia
-Diurnal variation: Normal in mid morning, low values in mid afternoon, and very low values near midnight.
TIBC/UIBC INCREASED IN:

-Iron deficiency anemia
-Acute & Chronic blood loss
-Acute liver damage
-Progesterone birth control pills
TIBC/UIBC DECREASED IN:

-Hemochromatosis
-Cirrhosis of the liver
-Thalassemia
-Anemia of infective & chronic disease
-Nephrosis
TRANSFERRIN SATURATION INCREASED IN:

- High Values in iron overload
- Raised transferrin saturation is an early indicator of Iron accumulation in hemochromatosis.
TRANSFERRIN SATURATION DECREASED IN:

- Low Values in iron deficiency
Page 8 of 12
DEPARTMENT OF IMMUNOLOGY
THYROID PROFILE TOTAL

Sample Type : SERUM
Total Triiodothyronine (T3) 1.15 ng/ml 0.61-1.81 CLIA
Total Thyroxine (T4) 7.6 ug/dL 4.5-10.9 CLIA
Thyroid Stimulating Hormone (TSH) 2.29 ulU/mL 0.35-5.50 CLIA
Kindly correlate clinically.

INTERPRETATION:
1. Serum T3, T4 and TSH are the measurements form three components of thyroid screening panel and are useful in diagnosing various disorders of thyroid gland
function.
2. Primary hyperthyroidism is accompanied by elevated serum T3 and T4 values along with depressed TSH levels.
3. Primary hypothyroidism is accompanied by depressed serum T3 and T4 values and elevated serum TSH levels.
4. Normal T4 levels accompanied by high T3 levels are seen in patients with T3 thyrotoxicosis. Slightly elevated T3 levels may be found in pregnancy and in
estrogen therapy while depressed levels may be encountered in severe illness, malnutrition, renal failure and during therapy with drugs like propanolol and
propylthiouracil.
5. Although elevated TSH levels are nearly always indicative of primary hypothyroidism, rarely they can result from TSH secreting pituitary tumors (secondary
hyperthyroidism).
6. Low levels of Thyroid hormones (T3, T4 & FT3, FT4) are seen in cases of primary, secondary and tertiary hypothyroidism and sometimes in non-thyroidal
illness also.
7. TSH levels are raised in primary hypothyroidism and are low in hyperthyroidism and secondary hypothyroidism.
9. REFERENCE RANGE :.
PREGNANCY TSH in uIU/mL Age TSH in uIU/mL
1st Trimester 0.60 - 3.40 0 – 4 Days 1.00 - 39.00
2nd Trimester 0.37 - 3.60 2 Weeks to 5 Months 1.70 – 9.10
3rd Trimester 0.38 – 4.04 6 Months to 20 Yrs. 0.70 – 6.40
>55 Yrs 0.50 - 8.90
(References range recommended by the American Thyroid Association)
Comments:
1. During pregnancy, Free thyroid profile (FT3, FT4 & Ultra-TSH) is recommended.
2. TSH levels are subject to circadian variation, reaches peak levels between 2-4 AM and at a minimum between 6-10 PM. The variation of the day has influence
on the measured serum TSH concentrations.
Test results released pertain to the specimen submitted, All test results are dependent on the quality of the sample received by the Laboratory., Test results may
show interlaboratory variations
Test results are not valid for medico legal purposes.
Page 9 of 12
25 HYDROXY VITAMIN D
Sample Type : SERUM
25 HYDROXY VITAMIN D-3 13.62 ng/ml 30-100 CLIA
INTERPRETATION:
LEVEL REFERENCE RANGE

Deficiency (serious deficient) < 20 ng/ml
Insufficiency (Deficient) 20-30 ng/ml
Sufficient (adequate) 30-100 ng/ml
Toxicity > 100 ng/ml
DECREASED LEVELS:
-Deficiency in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and Tetany.
-Inadequate exposure to sunlight.
-Dietary deficiency.
-Vitamin D malabsorption.
-Severe Hepatocellular disease.
-Drugs like Anticonvulsants.
-Nephrotic syndrome.
INCREASED LEVELS:
-Vitamin D intoxication.
COMMENTS:
-Vitamin D (Cholecalciferol) promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Vitamin D status is
best determined by measurement of 25 hydroxy vitamin D, as it is the major circulating form and has longer half life (2-3 weeks) than 1,
25 Dihydronxy vitamin D (5-8 hrs)., -The assay measures D3 (Cholecaciferol) metabolites of vitamin D., -25 (OH) D is influenced by
sunlight, latitude, skin pigmentation, sunscreen use and hepatic function., -Optimal calcium absorption requires vitamin D 25 (OH) levels
exceeding 75 nmol/L., -It shows seasonal variation, with values being 40-50% lower in winter than in summer., -Levels vary with age and
are increased in pregnancy.,-This is the recommended test for evaluation of vitamin D intoxication.
Test results released pertain to the specimen submitted, All test results are dependent on the quality of the sample received by the
Laboratory,Test results may show interlaboratory variations.
Page 10 of 12
Vitamcyanocobalaminin- B12 ()
Sample Type : SERUM
Vitamin B12 308.00 pg/mL 211-911 CLIA
Interpretation :
This test is most often done when other blood tests suggest a condition called megaloblastic anemia. Pernicious anemia is a form of
megaloblastic anemia caused by poor vitamin B12 absorption. This can occur when the stomach makes less of the substance the body
needs to properly absorb vitamin B12. Causes of vitamin B12 deficiency include:Diseases that cause malabsorption Lack of intrinsic factor,
a protein that helps the intestine absorb vitamin B12 Above normal heat production (for example, with hyperthyroidism) An increased
vitamin B12 level is uncommon in: Liver disease (such as cirrhosis or hepatitis) Myeloproliferative disorders (for example, polycythemia
vera and chronic myelogenous leukemia)
Test results released pertain to the specimen submitted, All test results are dependent on the quality of the sample received by the
Laboratory,Test results may show interlaboratory variations.
Page 11 of 12
DEPARTMENT OF CLINICAL PATHOLOGY

URINE ROUTINE EXAMINATION

Sample Type : URINE
PHYSICAL EXAMINATION
VOLUME 15 ml Measuring
COLOUR YELLOW
APPEARANCE SLIGHTLY
TURBID
CHEMICAL EXAMINATION
pH 6.00 5-8.5
SPECIFIC GRAVITY 1.0250 1.0050 - 1.0350
PROTEIN NEGATIVE Negative
GLUCOSE NEGATIVE Negative
KETONES NEGATIVE Negative
UROBILINOGEN NEGATIVE Negative
BILIRUBIN NEGATIVE Negative
BLOOD NEGATIVE Negative
LEUCOCYTE TRACE Negative
NITRITE NEGATIVE Negative
MICROSCOPIC EXAMINATION
PUS CELLS 4-6 cells/HPF 0-5 Microscopic
RED BLOOD CELLS NIL Cells/HPF NIL Microscopic
EPITHELIAL CELLS 8-10 Cells/HPF 0-5 Microscopic
CRYSTALS NIL /HPF NIL Microscopic
CASTS NIL /HPF NIL Microscopic
BUDDING YEAST CELLS NIL /HPF NIL Microscopic
BACTERIA NIL /HPF NIL Microscopic
PROTOZOA NIL /HPF NIL Microscopic
OTHER NIL
Page 12 of 12

Labreportnew

Uploaded by

Copyright:

Available Formats

Labreportnew

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Labreportnew

Uploaded by

Copyright:

Available Formats

Patient NAME : Mrs.

HIMANSHI Lab No : THS153180

COMPLETE BLOOD COUNT

MCHC 30.1 g/dl 31.5-34.5 Automated/Calculated

RDW-CV 14 % 11.6-14.0 Automated/Calculated

TOTAL LEUCOCYTE COUNT (TLC) 10.00 10^3/uL 4.0-10.0 Electrical impedance

DLC (Differential Leukocyte Count.)

ERYTHROCYTE SEDIMENTATION RATE

Glycosylated hemoglobin (HbA1c)

Note : Hemoglobin electrophoresis (HPLC method) is recommended for detecting hemoglobinopathy.

*** End Of Report ***

LIVER FUNCTION TEST

TRIGLYRIDES/HDL RATIO 3.26 Ratio 1.0-6.0 Calculated

Urea / Creatinine Ratio 45.21 Ratio 8-38 Calculated

Phosphorus 4.10 mg/dl 2.5-4.5 UV MOLYBDATE

SERUM IRON DECREASED IN:

TIBC/UIBC INCREASED IN:

TIBC/UIBC DECREASED IN:

TRANSFERRIN SATURATION INCREASED IN:

TRANSFERRIN SATURATION DECREASED IN:

*** End Of Report ***

THYROID PROFILE TOTAL

Kindly correlate clinically.

LEVEL REFERENCE RANGE

Laboratory,Test results may show interlaboratory variations.

Test results are not valid for medico legal purposes.

Laboratory,Test results may show interlaboratory variations.

Test results are not valid for medico legal purposes.

*** End Of Report ***

DEPARTMENT OF CLINICAL PATHOLOGY

URINE ROUTINE EXAMINATION

You might also like

* End Of Report *

* End Of Report *

* End Of Report *